Dan Raffi’s role as the Chief Operating Officer would be to strengthen Sim&Cure's leadership and expand the company's geographic footprints.
FREMONT, CA: “Dan brings with him extensive experience in leadership and in managing unique business transformations.” Mathieu Sanchez, Sim&Cure CEO states, “Bringing a seasoned leader like Dan will ensure the next phases of our transformation and will help us to reinforce our leadership in innovation using Digital twin and AI in endovascular procedures.” Dan Raffi has been appointed as the Chief Operating Officer and a member of the Board of Directors of Sim&Cure, a prominent medtech start-up that provides a unique software solution combining Digital twin and AI technologies to secure neurovascular therapy of cerebral aneurysms.
Dan is a seasoned executive in the healthcare industry with over ten years of experience. Dan has worked for a number of large pharmaceutical businesses, including Allergan (AbbVie) and Medtronic, a global leader in medical devices. Dan was Vice President of Global Marketing for Medtronic Neurovascular until recently, and before that, he oversaw the Neurovascular division in Europe, the Middle East, Africa, and Russia for three years. Dan built unique and revolutionary partnerships internationally with governments and several external partners such as MT2020, RapidAI, Viz.Ai, and Sim&Cure throughout his 7 years in Neurovascular.
Dan will work with Christophe Chnafa, Chief Innovation & Strategy Officer, to define the product portfolio roadmap to strengthen Sim&Cure's leadership, expand the company's geographic footprints, and define the next generation of partnerships with the rest of the industry and hospitals in his new role.
“I’ve been watching Sim&Cure for the past 7 years and I never forgot my first support to the company. There were 3 employees working in a “garage” (a kind of French Dream!). In 7 years, Sim&Cure established unique computational and AI algorithms which position their products as THE cutting-edge technology in endovascular procedures. This technology is already the standard of care across the globe as it reduces the procedure time, improves the safety and performance for patients and reduces the procedure cost for hospitals and healthcare systems. In the coming decade, AI will be the next revolution in the healthcare industry, and this is one of the reasons I decided to join Sim&Cure.” adds Dan Raffi.